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Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and serious complication after
pulmonary embolism (PE). Its incidence in the general population is around 3–30 cases per million. The
incidence of CTEPH after acute PE ranges between 0.1 and 8.8% [1–5]. In a meta-analysis including 4047
PE patients, the incidence of CTEPH was 2.8% (95% CI 1.5–4.1) in “PE survivors” without major
comorbidities [6]. In studies not using objective diagnostic criteria to diagnose CTEPH, the pooled
incidence was 6.3% (95% CI 4.1–8.4) [6].
To diagnose CTEPH, a number of tests are required. Transthoracic echocardiography (TTE) should always
be performed when CTEPH is suspected, but is not enough to support a treatment decision. It is
mandatory to demonstrate the combination of precapillary pulmonary hypertension (defined by mean
pulmonary arterial pressure (PAP) levels ⩾25 mmHg at rest) on right heart catheterisation and
mismatched perfusion defects on lung scan. All patients also need a multidetector computed tomography
angiography, magnetic resonance imaging or conventional pulmonary angiography to look for specific
signs such as ring-like stenosis, webs/slits and/or chronic total occlusions (pouch lesions or tapered
lesions) [7]. The prognosis of patients with CTEPH without treatment is poor [8], but early detection and
pulmonary endarterectomy (PEA) may improve outcomes considerably. In fact, the time elapsed between
the last PE episode and PEA influences the mortality rate [9]. However, a significant number of patients,
presumably 40%, develop CTEPH in the absence of prior acute PE [10, 11].
TTE is considered the first test in the diagnostic algorithm for CTEPH, but routine TTE in all patients
with PE is not cost-effective, given its low diagnostic yield for CTEPH of around 25% 6–12 months after
an acute episode of PE [12, 13]. Consequently, current guidelines from the European Society of
Cardiology/European Respiratory Society recommend that TTE is only considered in patients with
exercise/persistent dyspnoea several weeks after PE [7, 14]. The most common symptom of CTEPH
initially is progressive dyspnoea on exercise, although some patients with PE may transiently experience
some improvement in symptoms. Therefore, early identification of CTEPH soon after the PE is difficult.
A simple and noninvasive tool that could be used as a routine assessment in patients with acute PE might
help to discriminate those patients that could safely avoid further diagnostic tests. Recently, a clinical
prediction score for CTEPH was derived from three large prospective cohorts including 772 patients with
acute PE [15]. The authors built a clinical prediction score assigning points to six clinical variables:
unprovoked PE, known hypothyroidism, symptom onset >2 weeks before PE diagnosis, right ventricular
dysfunction on computed tomography or TTE, known diabetes mellitus, and thrombolytic therapy or
embolectomy. They considered the diagnosis very unlikely in patients scoring ⩽6 points. The sensitivity of
the score obtained with this threshold was 91% (95% CI 70–98%).
We tried to externally validate this score in a CTEPH rule-out strategy in 2256 patients with acute PE
included in the RIETE registry. Patients with history of heart failure or chronic pulmonary disease were
not considered for the study. All patients underwent TTE between 6 and 12 months after the PE episode.
Since RIETE has no information available on CTEPH diagnosis, we considered patients not to have
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CTEPH when a low probability of pulmonary hypertension was found on TTE, according to current
guideline recommendations [7, 16]: systolic PAP levels ⩽36 mmHg or peak tricuspid regurgitation velocity
⩽2.8 m·s−1 (or not measurable), and no additional TTE signs suggesting pulmonary hypertension (right
ventricle/left ventricle basal diameter ratio>1, diastolic right ventricle diameter >35 mm, right ventricle
hypokinesia, left ventricular eccentricity index >1.0 in systole and/or diastole and/or tricuspid annulus
plane systolic excursion <17 mm).
The flow-chart of patients appears in figure 1. From 25695 PE patients included in the RIETE registry, we
selected 2807 in whom a TTE was performed 6–12 months after acute PE. Finally, 2256 patients were
analysed. CTEPH was ruled out by TTE in 1670 (74%) patients, of whom 1295 were classified as
“low-risk” by the clinical prediction score (⩽6 points). Among the remaining 586 patients with “likely”
CTEPH on TTE, only 160 were classified as “high-risk” according to the score. In a “rule-out” strategy,
using the score would help to avoid 1295 (57%) unnecessary TTEs, but the proportion of false negatives
was 72.7% (95% CI 68.9–76.1%). In other words, the score would mistakenly suggest that TTE could be
avoided in 426 (19%) out of 2256 of patients.
The sensitivity of the score was 27.3% (95% CI 23.7–30.9%) and the negative predictive value 75.2% (95%
CI 73.2–77.3%). Others parameters, like specificity and positive predictive value are not relevant in this
approach since the aim of this study was to validate the score in a rule-out strategy. Even if a higher
threshold of ⩽8 points were applied this strategy would not be associated with a better sensitivity: 12.1%
(95% CI 9.4–14.7%).
Early diagnosis of CTEPH remains challenging, with a considerable delay between symptoms onset and
CTEPH diagnosis. The reported median time is ∼14 months, even in experienced centres [17]. CTEPH is
characterised by the classical “honeymoon”: since patients may worsen after an initial improvement. An
easily available score early after PE diagnosis may help clinicians to decide which patients would benefit
from a more thorough screening for CTEPH.
The potential benefit of CTEPH screening at the time of PE diagnosis is controversial, but some authors
have suggested this possibility to identify patients at high risk. In 2015, KLOK et al. [18] built CTEPH
rule-out criteria based on a normal N-terminal pro-brain natriuretic peptide (NT-proBNP) level and the
absence of three electrocardiographic characteristics in a prospective cohort of patients with PE undergoing
TTE during follow-up. The presence of pulmonary hypertension was unlikely in 81% based on TTE
criteria, with a sensitivity of 100% (95% CI 56–100%). The main limitations were that the validation was
only possible in 134 patients and at 6 months. Interestingly, however, no clinical variables were included in
the rule-out criteria, so some cases of “new onset” CTEPH could be previous to the acute PE episode.
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FIGURE 1 Flow chart of patients. PE: pulmonary embolism; TTE: transthoracic echocardiography; CTEPH:
chronic thromboembolic pulmonary hypertension.
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Our findings do not confirm the sensitivity and negative predictive value of the score obtained during the
derivation study [18]. The score may help us to avoid the up to 57% unnecessary TTEs, but with the risk
of a substantial number of false negative results. One of the advantages of our approach is that it has been
tested in a large sample of “real world” patients who underwent routine follow-up visits and one TTE
between 6 and 12 months after PE.
Our approach has a number of limitations. First, even though TTE is still recommended as the initial
noninvasive tool in the screening of PH, it may frequently be inaccurate in estimating systolic PAP levels [19].
Second, the RIETE registry was not initially designed to identify PE patients at risk for CTEPH, and there
is no information on a final confirmation of CTEPH in most of these patients. In addition, one of the
variables in the model (symptom onset >2 weeks before PE diagnosis) is not available in RIETE. Thus, we
replaced it with “isolated dyspnoea” at baseline and slightly modified the original score. Our main
strengths are the large number of PE patients in the registry (n=2256), and that the TTE criteria used for
defining very unlikely CTEPH were based on current guideline recommendations [7].
Our results suggest that a predictive score based on data obtained during the index PE is not sensitive
enough for a CTEPH rule-out strategy. With the aim of improving the diagnostic accuracy, other strategies
should be evaluated, such as a combination of a predictive score based on the index PE and more specific
biomarkers, for example NT-proBNP, during follow-up [18].
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